Anna D. Barker

4.0k total citations
31 papers, 899 citations indexed

About

Anna D. Barker is a scholar working on Molecular Biology, Immunology and Cancer Research. According to data from OpenAlex, Anna D. Barker has authored 31 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Immunology and 6 papers in Cancer Research. Recurrent topics in Anna D. Barker's work include Cancer Genomics and Diagnostics (5 papers), Bioinformatics and Genomic Networks (3 papers) and Immune Cell Function and Interaction (3 papers). Anna D. Barker is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Bioinformatics and Genomic Networks (3 papers) and Immune Cell Function and Interaction (3 papers). Anna D. Barker collaborates with scholars based in United States, Germany and United Kingdom. Anna D. Barker's co-authors include Francis S. Collins, Artemio A. Ovejera, David P. Houchens, George Poste, Dorothy Farrell, Piotr Grodzinski, Nicholas J. Panaro, Melvin S. Rheins, Joe Alper and Mustafa Khasraw and has published in prestigious journals such as Journal of Clinical Oncology, ACS Nano and Cancer Research.

In The Last Decade

Anna D. Barker

28 papers receiving 856 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna D. Barker United States 13 407 277 188 113 107 31 899
Konstantina Grosios United Kingdom 13 588 1.4× 189 0.7× 410 2.2× 74 0.7× 73 0.7× 17 1.1k
Phyllis Wachsberger United States 18 683 1.7× 331 1.2× 224 1.2× 53 0.5× 127 1.2× 41 1.1k
Marion T. Weigel Germany 16 481 1.2× 275 1.0× 338 1.8× 132 1.2× 45 0.4× 27 1.1k
Ariosto S. Silva United States 12 479 1.2× 526 1.9× 303 1.6× 187 1.7× 77 0.7× 21 1.1k
Augusto Rendon United Kingdom 16 377 0.9× 126 0.5× 131 0.7× 178 1.6× 216 2.0× 30 1.0k
Bea Pauwels Belgium 16 439 1.1× 188 0.7× 356 1.9× 30 0.3× 123 1.1× 30 949
Catherine M. Shachaf United States 13 784 1.9× 279 1.0× 381 2.0× 126 1.1× 52 0.5× 22 1.2k
Dora Cavallo‐Medved Canada 21 601 1.5× 564 2.0× 437 2.3× 56 0.5× 92 0.9× 37 1.3k
Donald J. Johann United States 18 805 2.0× 315 1.1× 389 2.1× 56 0.5× 120 1.1× 59 1.4k
Steven A. Enkemann United States 18 783 1.9× 246 0.9× 414 2.2× 77 0.7× 56 0.5× 31 1.3k

Countries citing papers authored by Anna D. Barker

Since Specialization
Citations

This map shows the geographic impact of Anna D. Barker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna D. Barker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna D. Barker more than expected).

Fields of papers citing papers by Anna D. Barker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna D. Barker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna D. Barker. The network helps show where Anna D. Barker may publish in the future.

Co-authorship network of co-authors of Anna D. Barker

This figure shows the co-authorship network connecting the top 25 collaborators of Anna D. Barker. A scholar is included among the top collaborators of Anna D. Barker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna D. Barker. Anna D. Barker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barker, Anna D., et al.. (2023). An Inflection Point in Cancer Protein Biomarkers: What was and What's Next. Molecular & Cellular Proteomics. 22(7). 100569–100569. 14 indexed citations
2.
Barker, Anna D. & Kenneth H. Buetow. (2019). Abstract SY36-03: Viewing cancer as a complex adaptive system and managing immunotherapy as “homeostatic reset”. Cancer Research. 79(13_Supplement). SY36–3. 1 indexed citations
3.
Magee, Daniel, Zoran Gatalica, Adam Stark, et al.. (2018). Poly-ligand profiling (PLP) to differentiate pancreatic cancer patients who benefit from gemcitabine+evofosfamide versus gemcitabine+placebo treatment.. Journal of Clinical Oncology. 36(15_suppl). 12067–12067. 2 indexed citations
4.
Poste, George, Carolyn C. Compton, & Anna D. Barker. (2014). The national biomarker development alliance: confronting the poor productivity of biomarker research and development. Expert Review of Molecular Diagnostics. 15(2). 211–218. 25 indexed citations
5.
Ptak, Krzysztof, Dorothy Farrell, Nicholas J. Panaro, Piotr Grodzinski, & Anna D. Barker. (2010). The NCI Alliance for Nanotechnology in Cancer: achievement and path forward. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. 2(5). 450–460. 19 indexed citations
6.
Farrell, Dorothy, et al.. (2010). Recent Advances from the National Cancer Institute Alliance for Nanotechnology in Cancer. ACS Nano. 4(2). 589–594. 62 indexed citations
7.
Barker, Anna D.. (2010). Novel Approach: Reading Courses as an Alternative to Prison. UST Research Online (University of St. Thomas - Minnesota).
8.
Collins, Francis S. & Anna D. Barker. (2007). Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies.. PubMed. 296(3). 50–7. 138 indexed citations
9.
Collins, Francis S. & Anna D. Barker. (2007). Mapping the Cancer Genome. Scientific American. 296(3). 50–57. 141 indexed citations
10.
Barker, Anna D., et al.. (2003). Legislative History of the National Cancer Program. 1 indexed citations
11.
Barker, Anna D., et al.. (2003). Public Attitudes Concerning Cancer. 3 indexed citations
12.
Barker, Anna D., et al.. (2003). The Government and Cancer Medicine. 1 indexed citations
13.
Sigal, Ellen V. & Anna D. Barker. (1998). Report from THE MARCH Research Task Force. September 25-26, 1998.. PubMed. 58(23). 5590–627. 3 indexed citations
14.
Barker, Anna D., et al.. (1979). EFFECTS OF THYMOSIN ON CYTOTOXICITY AND VIRUS PRODUCTION IN AKR MICE*. Annals of the New York Academy of Sciences. 332(1). 70–80. 4 indexed citations
15.
Ovejera, Artemio A., David P. Houchens, & Anna D. Barker. (1978). Chemotherapy of human tumor xenografts in genetically athymic mice.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 8(1). 50–6. 164 indexed citations
16.
Barker, Anna D., et al.. (1975). In vivo and in vitro effects of thymosin treatment in spontaneous and first-transplant akr leukemias. Abstr.. The Mouseion at the JAXlibrary (Jackson Laboratory). 34(3). 1024. 1 indexed citations
17.
Barker, Anna D. & Samuel D. Waksal. (1975). IN VIVO STUDIES OF DIFFERENTIATION OF THYMUS‐DERIVED LEUKEMIC CELLS*. Annals of the New York Academy of Sciences. 249(1). 484–491. 2 indexed citations
18.
Barker, Anna D., et al.. (1973). Immunologic Responsiveness of Young AKR Mice to Iodoacetate and to Iodoacetate-Treated Tumor Cells. Immunological Communications. 2(4). 343–352. 1 indexed citations
19.
Rheins, Melvin S., Anna D. Barker, & Henry E. Wilson. (1971). Therapeutic effects of a series of non-viral interferon inducers on a viral-induced leukemia. Canadian Journal of Microbiology. 17(10). 1259–1265. 2 indexed citations
20.
Barker, Anna D., Melvin S. Rheins, & Henry E. Wilson. (1971). Amelioration of Friend Virus Leukemia by Sequential Administration of Viral and Nonviral Interferon Inducers. Experimental Biology and Medicine. 137(3). 981–987. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Konstantina Grosios Breakdown of academic impact, for papers by Phyllis Wachsberger Breakdown of academic impact, for papers by Marion T. Weigel Breakdown of academic impact, for papers by Ariosto S. Silva Breakdown of academic impact, for papers by Augusto Rendon Breakdown of academic impact, for papers by Bea Pauwels Breakdown of academic impact, for papers by Catherine M. Shachaf Breakdown of academic impact, for papers by Dora Cavallo‐Medved Breakdown of academic impact, for papers by Donald J. Johann Breakdown of academic impact, for papers by Steven A. Enkemann
Rankless by CCL
2026